Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 7, 2006, Pages 2542-2547

  Pilz, Stefan ^a   Scharnagl, Hubert ^a   Tiran, Beate ^a   Seelhorst, Ursula ^b   Wellnitz, Britta ^b   Boehm, Bernhard O ^c   Schaefer, Jürgen R ^d   März, Winfried ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Ludwigshafen Risk and Cardiovascular Health Study Nonprofit LLC   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

AGED; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; CORONARY DISEASE; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33745776303     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0195     Document Type: Article

References (39)

1. Bays H, Mandarino L, DeFronzo RA 2004 Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478
2. Poynten AM, Gan SK, Kriketos AD, Campbell LV, Chisholm DJ 2005 Circulating fatty acids, non-high density lipoprotein cholesterol, and insulin-infused fat oxidation acutely influence whole body insulin sensitivity in non-diabetic men. J Clin Endocrinol Metab 90:1035-1040
3. Stich V, Berlan M 2004 Physiological regulation of NEFA availability: lipolysis pathway. Proc Nutr Soc 63:369-374
4. Randle PJ, Garland PB, Hales CN, Newsholme EA 1963 The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789
5. Schaefer JR, Maisch B, Klumpp S, Krieglstein J 2005 Why does atherosclerosis occur where it occurs? Atherosclerosis 180:417-418
6. Hufnagel B, Dworak M, Soufi M, Mester Z, Zhu Y, Schaefer JR, Klumpp S, Krieglstein J 2005 Unsaturated fatty acids isolated from human lipoproteins activate protein phosphatase type 2Cβ and induce apoptosis in endothelial cells. Atherosclerosis 180:245-254
7. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD 1997 Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100:1230-1239
8. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD 2000 Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49:1231-1238
9. Carlsson M, Wessman Y, Almgren P, Groop L 2000 High levels of nonesterified fatty acids are associated with increased familial risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 20:1588-1594
10. Pirro M, Mauriege P, Tchernof A, Cantin B, Dagenais GR, Despres JP, Lamarche B 2002 Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Atherosclerosis 160:377-384
11. Hendrickson SC, Louis JD, Lowe JE, Abdel-aleem S 1997 Free fatty acid metabolism during myocardial ischemia and reperfusion. Mol Cell Biochem 166:85-94
12. Oliver MF, Opie LH 1994 Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 343:155-158
13. Oliver MF 2002 Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med 112:305-311
14. Manzella D, Barbieri M, Rizzo MR, Ragno E, Passariello N, Gambardella A, Marfella R, Giugliano D, Paolisso G 2001 Role of free fatty acids on cardiac autonomic nervous system in noninsulin-dependent diabetic patients: effects of metabolic control. J Clin Endocrinol Metab 86:2769-2774
15. Korge P, Honda HM, Weiss JN 2003 Effects of fatty acids in isolated mitochondria: implications for ischemic injury and cardioprotection. Am J Physiol Heart Circ Physiol 285:259-269
16. Azzazy HM, Pelsers MM, Christenson RH 2006 Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 52:19-29
17. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ 2003 Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111:419-426
18. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE 2005 Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96:225-233
19. Jouven X, Charles MA, Desnos M, Ducimetiere P 2001 Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 104:756-761
20. Charles MA, Fontbonne A, Thibult N, Claude JR, Warnet JM, Rosselin G, Ducimetiere P, Eschwege E 2001 High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris prospective study. Am J Epidemiol 153:292-298
21. Forsblom CM, Sane T, Groop PH, Tötterman KJ, Kallio M, Saloranta C, Laasonen L, Summanen P, Lepäntalo M, Laatikainen L, Matikainen E, Teppo AM, Koskimies S, Groop L 1998 Risk factors for mortality in type II (noninsulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR 4. Diabetologia 41:1253-1262
22. Winkelmann BR, März W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J 2001 Rationale and design of the LURIC study: a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2:1-73
23. Boehm BO, Schiekofer S 2006 The metabolic syndrome. Heart Metab 30:7-10
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
25. Korvald C, Elevenes OP, Myrmel T 2000 Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Phys Heart Circ Physiol 278:1345-1351
26. Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS, Stanley WC 2003 Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc Res 59:143-151
27. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK 2001 Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103:2441-2446
28. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K 2004 Uncoupling proteins in human heart. Lancet 364:1786-1788
29. 1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction. Circulation 102:2070-2075
30. Opie LH 2004 The metabolic vicious cycle in heart failure. Lancet 364:1733-1734
31. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M, Jordan J 2005 Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 90:3622-3628
32. Lommi J, Kupari M, Yki-Järvinen H 1998 Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 81:45-50
33. Oram JF, Bornfeldt KE 2004 Direct effects of long-chain non-esterified fatty acids on vascular cells and their relevance to macrovascular complications of diabetes. Front Biosci 9:1240-1253
34. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P 2003 Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52:2882-2887
35. Paolisso G, Gualdiero P, Manzella D, Rizzo MR, Tagliamonte MR, Gambardella A, Verza M, Gentile S, Varricchio M, D'Onofrio F 1997 Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. Am J Cardiol 80:932-937
36. Frayn KN 2005 Plasma non-esterified fatty acids: why are we not measuring them routinely? Ann Clin Biochem 42:413-414
37. Folmes CD, Clanachan AS, Lopaschuk GD 2005 Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep 7:63-70
38. Frayn KN, Fielding BA, Karpe F 2005 Adipose tissue fatty acid metabolism and cardiovascular disease. Curr Opin Lipidol 16:409-415
39. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, Lopaschuck GD 2004 Malonyl coenzyme A decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94:78-84